Applied Clinical Trials-05-01-2006

CSR is in the best interest of the public at large...and the pharmaceutical company itself.

New EU legislation heralds a difficult funding environment for nonprofit research centers.

A growing number of sponsors and regulators are recognizing that accredited organizations are more likely to be compliant.

The use of composite endpoints are being regarded as a useful strategy, but caution must be applied as there are both risks and benefits.

EU Council supports pediatric medicines proposal, but adds some changes.

Tools for Clinical Trials Professionals

The much anticipated list features initiatives in biomarkers and research productivity.